Effect of erlotinib combined with paclitaxel and cisplatin in treatment of advanced non-small cell lung cancer / 新乡医学院学报

ABSTRACT

Objective To investigate the clinical effect of erlotinib combined with paclitaxel and cisplatin in the treat-ment of advanced non-small cell lung cancer(NSCLC). Methods A total of 200 patients with stage TNM Ⅲ - Ⅳ NSCLC in the First Affiliated Hospital of Nanyang Medical College from April 2014 and April 2015 were selected as the subjects. The pa-tients were divided into observation group and control group according to the chemotherapy,100 cases in each group. The pa-tients in the control group were treated with combined chemotherapy of paclitaxel and cisplatin. The patients in the observation group were treated with combined chemotherapy of erlotinib,paclitaxel and cisplatin. The levels of serum carcinoembryonic an-tigen(CEA ),carbohydrate antigen 125 (CA125 ),carbohydrate antigen 199 (CA199 ) and cytokeratin 19 fragment (CYFRA211)of the patients in the two groups were detected before and after two cycles of chemotherapy. The adverse reac-tions of the patients in the two groups were observed during the treatment. The curative effect was evaluated according to the re-sponse evaluation criteria in solid tumors formulated by World Health Organization. The patients in the two groups were fol-lowed up for two years,and the survival rate of the patients was statistically analyzed. Results There was no significant differ-ence in serum CEA,CA125,CA199 and CYFRA211 levels between the two groups before treatment(P > 0. 05). The levels of serum CEA,CA125,CA199 and CYFRA211 after treatment were significantly lower than those before treatment in the two groups(P < 0. 05). The levels of serum CEA,CA125,CA199 and CYFRA211 in the observation group were significantly lower than those in the control group after treatment(P < 0. 05). The total effective rate in the observation group and the control group was 74. 0％(74 / 100)and 57. 0％(57 / 100)respectively,the total effective rate in the observation group was signifi-cantly higher than that in the control group(χ2 = 6. 395,P < 0. 05). The incidence of adverse reactions in the observation group and the control group was 45. 0％(45 / 100)and 78. 0％(78 / 100)respectively,the incidence of adverse reactions in the ob-servation group was significantly lower than that in the control group(χ2 = 22. 997,P < 0. 05). The 2-year survival rate in the observation group and the control group was 90. 0％(90 / 100)and 75. 0％(75 / 100)respectively,the 2-year survival rate in the observation group was significantly higher than that in the control group(χ2 = 8. 028,P < 0. 05). Conclusion The com-bined chemotherapy of erlotinib,paclitaxel and cisplatin can significantly reduce the levels of serum tumor markers,improve the therapeutic effect and survival rate,and reduce the incidence of chemical therapy related adverse reactions in patients with ad-vanced NSCLC.